Impact of Dexmedetomidine on Breast Cancer Recurrence After Surgery

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Dexmedetomidine is widely used as an anaesthetic for general anesthesia during surgery. Previous studies in cells and animals show that dexmedetomidine may promote cancer growth. The purpose of present study is to examine whether utilization of dexmedetomidine in patients undergoing surgery for primary breast cancer increases breast cancer recurrence and metastasis, and to investigate its effects on the patients' immune system.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RenJi Hospital
• Collaborators: Shanghai 10th People's Hospital; Shanghai Pudong Hospital; Shanghai Seventh People's Hospital; Shanghai Tongji Hospital, Tongji University School of Medicine
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• ASA grade I-III

• Age range of 18 to75

• Patients diagnosed primary breast cancer(T2-3, N0-2, M0)

• Patients will have elective adenomammectomy

Exclusion Criteria:

• with history of breast operation

• Patients diagnosed carcinoma erysipelatodes

• Severe liver, renal, brain or lung disease

• with history of opioid addiction

• Patients diagnosed metastatic breast cancer